Immuneel Therapeutics Raises ₹100 Crore in Series B Funding to Expand Cancer Cell Therapy Business
Indian biotechnology company Immuneel Therapeutics has secured ₹100 crore (approximately $10.5 million) in a Series B funding round, attracting participation from both new and existing investors as it accelerates the development and commercialization of advanced cancer therapies. The latest funding round saw investments from Singularity AMC, Rainmatter by Zerodha, and several high-net-worth individuals. Existing backers … Read more